The Evolvement of Imaging in ccRCC

Now Viewing

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

Evolution of Imaging in Renal Cell Carcinoma (RCC)

Main Discussion Topics:

• Cross-sectional imaging with pre- and postcontrast assessment remains the cornerstone of renal mass evaluation.
• Advanced software developments now allow for better assessment of images, potentially helping predict benign vs malignant masses.
• Ongoing efforts to develop a “clear cell RCC score” based on MRI parameters to identify clear cell carcinoma vs benign tumors

Key Points for Physicians:

• Cross-sectional imaging with contrast remains essential for initial evaluation.
• New software assessment tools may improve diagnostic accuracy.
• Specialized MRI parameters show promise for distinguishing clear cell RCC from other masses.

Notable Insights:

The panel emphasized that although advanced imaging techniques are emerging, the fundamental approach of cross-sectional imaging with contrast has remained consistent for decades.

Clinical Significance:

New image processing technologies are enhancing traditional imaging modalities, potentially allowing for better risk stratification without increasing invasiveness.